Apparently, there were design reasons why for electronic calculations a different mathematical formulation was more efficient. The competing manufacturers would discover this fact one by one, and Zuse was worried that someone may question his integriry, thinking he was the source of the leak. But no one did.
Michael Hanack (the materials chemist) used a different strategy: he would not patent anything so his inventions could be used my any market participant, and he would consult for all of them.
On the other hand, everyone is looking forward to the day the aptamer patent runs out. Uptake is limited (and you'd think that CRISPR/CAS9 has the same problem) because of unreasonableness (in case of CRISPR uncertainty) around licensing.